MaxCyte CFO Set to Transition in 2026, Initiates Successor Search

miércoles, 12 de noviembre de 2025, 4:09 pm ET1 min de lectura
MXCT--

MaxCyte announces CFO Douglas Swirsky's planned transition in H1 2026. Swirsky will remain CFO until a successor is appointed, and the company has initiated a search process. Following the transition, Swirsky will continue in an advisory capacity. The transition is not expected to impact operations, results, or strategic priorities.

MaxCyte CFO Set to Transition in 2026, Initiates Successor Search

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios